The Latest Breaking News from MarketBeat

Lowe’s Stock Eyes New Highs as Growth, Dividends Drive Gains

Lowe's better-than-expected quarter and capital return are lifting market sentiment, and the stock is on track to hit new highs this year.

MarketBeat · Feb 28, 2025

March’s Hottest Stocks: 5 Buys to Consider Now

These five stocks present compelling buys for investors in February because they have tailwinds to drive their businesses and offer value to investors.

MarketBeat · Feb 28, 2025

Salesforce’s Hidden Strengths Could Fuel a Powerful Rebound

Salesforce is the leading CRM platform and is consolidating its position with new products like Data Cloud and Agentforce that resonate with clients.

MarketBeat · Feb 28, 2025

Do GM Stock Buybacks Make the Stock Buyable For Investors?

General Motors has just announced a multibillion-dollar buyback program. What impact does this have for investing in the name?

MarketBeat · Feb 27, 2025

Will Alibaba’s $53B AI Bet Be the Key to Tech Supremacy?

Is the rally is Alibaba shares just getting started after its strong earnings and announcement that it will invest $53 billion in AI and cloud computing?

MarketBeat · Feb 27, 2025

Builders FirstSource Is Laying the Foundation for a Rebound

Builders FirstSource is trading at low valuations but its 30+ acquisitions since 2020 has helped grow its moat throughout the nation's geographies.

MarketBeat · Feb 27, 2025

Domino’s Pizza Delivers a Buying Opportunity

Domino's Pizza is sustaining growth and widening its margin despite business headwinds. The company expects to post mid-single-digit growth this year.

MarketBeat · Feb 27, 2025

These Consumer Staples Shine Amid Market Turmoil

The consumer staples sector has outperformed the slumping market in recent days, with the XLP ETF thriving as a defensive standout amid economic fears.

MarketBeat · Feb 27, 2025

Regeneron: Is It the Perfect Biotech Stock for Value and Growth?

Regeneron is trading at historically low valuations as its Dupixent blockbuster drug could get a 30% increase in TAM if the FDA approves its use in COPD.

MarketBeat · Feb 27, 2025

Axon: Long-Term Outlook Is Strong Despite Federal Budget Worries

Federal budget cut worries hit Axon Enterprise shares hard. Can this stock, with a $129 billion total addressable market, rise above these fears?

MarketBeat · Feb 27, 2025